Frances Stocks Allen is a life sciences associate in the firm's London office. Ms. Stocks Allen practices in the firm’s Corporate Department, focusing primarily on transactional, licensing, intellectual property, and regulatory matters.
Ms. Stocks Allen advises on a broad spectrum of licensing
and other complex commercial and intellectual property arrangements including licensing,
distribution, supply, and complex corporate separation and divestment in the
life sciences sector. Ms. Stocks Allen also has expertise in EU and
UK regulatory issues and data privacy, including the General Data Protection Regulation (GDPR).
In 2017, Ms. Stocks Allen was seconded to the firm's Silicon
Valley office to work on cutting-edge biotechnology and licensing matters in
the life sciences sector. In 2015, Ms. Stocks Allen was seconded in-house to
Allergan, where she worked as part of the global commercial team, advising on
licensing and other commercial arrangements, and assisting with the
implementation of its US$66 billion acquisition by Actavis.
Ms. Stocks Allen is a Committee member of Women in
Law London (WILL), an active professional network with approximately 2,000
members, promoting the advancement of women solicitors.
Ms. Stocks Allen's representative transactions include advising:
- Allergan plc on all commercial, licensing, supply, quality, safety, separation, and transitional matters in connection with its US$40.5 billion divestment of its global generic pharmaceuticals business to Teva Pharmaceutical Industries Ltd
- A women's health products provider on all pre-closing commercial, licensing, supply, quality, safety, separation, and transitional matters in connection with its acquisition of certain women’s health products from a leading pharamceutical company
- Guardant Health in connection with its strategic joint venture with SoftBank, including negotiation of the joint venture, licensing, distribution, and assignment agreements
- A leading genetic engineering company in the negotiation of a research and collaboration agreement with a research institute in respect of the research institute's proprietary technology for the development of gene and cellular therapies for the diagnosis, treatment, and prevention of diseases and conditions, including, but not limited to primary immunodeficiencies and auto-immune disease
- A leading genetic engineering company in the negotiation of a research and collaboration agreement with a pharmaceutical company in respect of the pharmaceutical company's proprietary technology in the formulation, use, and manipulation of synthetic DNA
- A clinical stage UK-based biopharmaceutical company focused on rare and specialty diseases on its exclusive license agreement with a multinational biopharmaceutical company for an oral inhibitor of neutrophil elastase
- A specialty pharmaceutical company on the negotiation of an exclusive license agreement and exclusive supply agreement with a research and diagnostic development company for use of its proprietary cell isolation, detection, and analysis technology in the field of early cancer screening
- A pharmaceutical corporation on the negotiation of a Co-Promotion Agreement with a US-based manufacturer of pharmaceutical products for an anaplastic lymphoma kinase (ALK) inhibitor product
- A biotechnology company in connection with complex licensing and privacy compliance matters, including its exclusive in-licensing of assets from a Swiss multinational healthcare company
- Meda AB on all commercial, regulatory, separation, and transitional arrangements in relation to its disposal of Euromed SA, a leading European manufacturer of herbal extracts and natural active substances, to The Riverside Company
- Actavis on its divestment of part of its Western European generics sales and marketing business to Aurobindo